BR112022000529A2 - Composição farmacêutica - Google Patents
Composição farmacêuticaInfo
- Publication number
- BR112022000529A2 BR112022000529A2 BR112022000529A BR112022000529A BR112022000529A2 BR 112022000529 A2 BR112022000529 A2 BR 112022000529A2 BR 112022000529 A BR112022000529 A BR 112022000529A BR 112022000529 A BR112022000529 A BR 112022000529A BR 112022000529 A2 BR112022000529 A2 BR 112022000529A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- compositions
- relates
- psk9
- hydroxybenzoyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
composição farmacêutica. a invenção refere-se a composições farmacêuticas que compreendem um inibidor de pcsk9, tal como um peptídeo egf(a) e um sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico. a invenção refere-se ainda a processos para a preparação de tais composições, e ao uso destas na medicina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19190506 | 2019-08-07 | ||
PCT/EP2020/072227 WO2021023855A1 (en) | 2019-08-07 | 2020-08-07 | Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022000529A2 true BR112022000529A2 (pt) | 2022-03-03 |
Family
ID=67551283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022000529A BR112022000529A2 (pt) | 2019-08-07 | 2020-08-07 | Composição farmacêutica |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220323544A1 (pt) |
EP (1) | EP4009958A1 (pt) |
KR (1) | KR20220046565A (pt) |
CN (1) | CN114222581A (pt) |
AR (1) | AR122299A1 (pt) |
AU (1) | AU2020326265A1 (pt) |
BR (1) | BR112022000529A2 (pt) |
CA (1) | CA3144618A1 (pt) |
CO (1) | CO2022000575A2 (pt) |
IL (1) | IL289505A (pt) |
MX (1) | MX2022000889A (pt) |
PE (1) | PE20220486A1 (pt) |
TW (1) | TW202120118A (pt) |
WO (1) | WO2021023855A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240036563A (ko) * | 2021-07-15 | 2024-03-20 | 노보 노르디스크 에이/에스 | N-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 정제 |
WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
ATE309197T1 (de) | 1999-02-05 | 2005-11-15 | Emisphere Tech Inc | Verfahren zur herstellung alkylierter salicylamide |
WO2001092206A1 (en) | 2000-06-02 | 2001-12-06 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
MX2009002121A (es) | 2006-09-07 | 2009-05-20 | Hoffmann La Roche | Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico. |
PL2651398T3 (pl) | 2010-12-16 | 2018-05-30 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego |
CA2837658A1 (en) | 2011-06-20 | 2012-12-27 | Genentech, Inc. | Pcsk9-binding polypeptides and methods of use |
ES2965469T3 (es) * | 2012-03-22 | 2024-04-15 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y preparación de estas |
ES2952874T3 (es) | 2012-03-22 | 2023-11-06 | Novo Nordisk As | Composiciones de péptidos GLP-1 y preparación de estas |
HRP20220720T1 (hr) | 2016-01-13 | 2022-09-30 | Novo Nordisk A/S | Analozi egf(a) s masnim kiselinama kao supstituentima |
EP3474875A1 (en) * | 2016-06-24 | 2019-05-01 | H. Hoffnabb-La Roche Ag | Compositions and methods for treating cardiovascular disease |
US20200165313A1 (en) | 2017-07-19 | 2020-05-28 | Novo Nordisk A/S | Egf(a) analogues, preparation, formulations and uses thereof |
-
2020
- 2020-08-07 WO PCT/EP2020/072227 patent/WO2021023855A1/en unknown
- 2020-08-07 BR BR112022000529A patent/BR112022000529A2/pt not_active Application Discontinuation
- 2020-08-07 TW TW109126752A patent/TW202120118A/zh unknown
- 2020-08-07 CN CN202080055600.1A patent/CN114222581A/zh not_active Withdrawn
- 2020-08-07 CA CA3144618A patent/CA3144618A1/en not_active Withdrawn
- 2020-08-07 KR KR1020227004059A patent/KR20220046565A/ko unknown
- 2020-08-07 AR ARP200102265A patent/AR122299A1/es unknown
- 2020-08-07 MX MX2022000889A patent/MX2022000889A/es unknown
- 2020-08-07 PE PE2022000111A patent/PE20220486A1/es unknown
- 2020-08-07 EP EP20750288.1A patent/EP4009958A1/en not_active Withdrawn
- 2020-08-07 AU AU2020326265A patent/AU2020326265A1/en not_active Withdrawn
- 2020-08-07 US US17/628,697 patent/US20220323544A1/en not_active Abandoned
-
2021
- 2021-12-29 IL IL289505A patent/IL289505A/en unknown
-
2022
- 2022-01-24 CO CONC2022/0000575A patent/CO2022000575A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2022000889A (es) | 2022-02-14 |
AU2020326265A1 (en) | 2022-02-03 |
AR122299A1 (es) | 2022-08-31 |
PE20220486A1 (es) | 2022-04-04 |
CO2022000575A2 (es) | 2022-04-29 |
EP4009958A1 (en) | 2022-06-15 |
CN114222581A (zh) | 2022-03-22 |
WO2021023855A1 (en) | 2021-02-11 |
KR20220046565A (ko) | 2022-04-14 |
IL289505A (en) | 2022-02-01 |
TW202120118A (zh) | 2021-06-01 |
CA3144618A1 (en) | 2021-02-11 |
US20220323544A1 (en) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020009997A2 (es) | Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante | |
BR112022000490A2 (pt) | Composição farmacêutica | |
BR112022007718A2 (pt) | Composição farmacêutica, e, métodos de tratamento de um sujeito em necessidade e para produção de uma composição farmacêutica sólida | |
CL2020002797A1 (es) | Composiciones sólidas que comprenden un agonista de glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
CL2019003324A1 (es) | Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745) | |
PE20200335A1 (es) | Compuestos que inhiben la proteina mcl-1 | |
CO2022000575A2 (es) | Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
CL2010000434A1 (es) | Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica. | |
CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
BR112017028616A2 (pt) | acentuador de inibidores de homólogo de zeste 2 | |
UY38069A (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
ECSP21082195A (es) | Formas sólidas de un inhibidor de glyt1 | |
AR114324A1 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
BR112019007543A2 (pt) | inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase | |
CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). | |
CL2017003201A1 (es) | Variantes de il-37 | |
CO2024000581A2 (es) | Comprimido que comprende una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
AR122297A1 (es) | Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
CO2024005252A2 (es) | Dendrones peptídicos y métodos de uso de los mismos | |
CL2022002932A1 (es) | Composiciones y métodos para suministrar agentes farmacéuticamente activos | |
AR110548A1 (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares | |
BR112021021230A8 (pt) | Forma de cristal de composto inibidor de wee1 e uso do mesmo | |
BR112017027850A2 (pt) | composto, composição farmacêutica e uso de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B10A | Cessation: cessation confirmed |